Covered recipient · General Payments record
PAOLA MANSILLA-LETELIER
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$2,229.06
61 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,161.39 | 57 |
| Consulting Fee | $1,050.00 | 2 |
| Travel and Lodging | $17.67 | 2 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Abbott Laboratories | $1,310.25 | 15 |
| Novo Nordisk Inc | $327.70 | 16 |
| SANOFI-AVENTIS U.S. LLC | $149.87 | 8 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $143.42 | 7 |
| Bayer HealthCare Pharmaceuticals Inc. | $60.19 | 3 |
| Eli Lilly Export S.A. Puerto Rico Branch | $59.32 | 3 |
| AstraZeneca Pharmaceuticals LP | $59.01 | 3 |
| Merck Sharp & Dohme LLC | $39.98 | 2 |
| PBG PUERTO RICO LLC | $36.38 | 2 |
| Janssen Pharmaceuticals, Inc | $23.09 | 1 |
| Dexcom, Inc. | $19.85 | 1 |
Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PAOLA MANSILLA-LETELIER
NPI 1669621736 · CMS profile ID 553080
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
BAYAMON, PR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1669621736?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PAOLA MANSILLA-LETELIER, NPI 1669621736, CMS profile ID 553080. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669621736?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). PAOLA MANSILLA-LETELIER, NPI 1669621736, CMS profile ID 553080. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669621736?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- PAOLA MANSILLA-LETELIER, NPI 1669621736, CMS profile ID 553080, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1669621736?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
61 matching records · $2,229.06 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–61 of 61.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.98 | 03/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944402293 | CMS |
| Novo Nordisk Inc | $10.58 | 03/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899539697 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23.41 | 02/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887702763 | CMS |
| Abbott Laboratories | $19.98 | 02/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920536321 | CMS |
| Eli Lilly Export S.A. Puerto Rico Branch | $20.54 | 02/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918245037 | CMS |
| Novo Nordisk Inc | $18.19 | 02/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 898982039 | CMS |
| PBG PUERTO RICO LLC | $20.33 | 02/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949119609 | CMS |
| SANOFI-AVENTIS U.S. LLC | $20.44 | 02/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939020389 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.11 | 02/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914970191 | CMS |
| Abbott Laboratories | $20.46 | 01/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920521311 | CMS |
| Novo Nordisk Inc | $19.73 | 01/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899432447 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,211,279.17 | 30 |
| PY2024 | Recipient | $36,871.44 | 4 |
| PY2024 | Principal investigator | $893,244.47 | 16 |
| PY2023 | Recipient | $38,624.12 | 110 |
| PY2023 | Principal investigator | $553,093.12 | 6 |
| PY2022 | Recipient | $116,381.20 | 165 |
| PY2022 | Principal investigator | $424,049.00 | 5 |
| PY2021 | Recipient | $442,367.50 | 4 |
| PY2021 | Principal investigator | $3,762.79 | 13 |
| PY2020 | Recipient | $11,009.81 | 3 |
| PY2020 | Principal investigator | $15,808.75 | 2 |
| PY2019 | Recipient | $3,365.95 | 1 |
| PY2019 | Principal investigator | $15,134.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
30 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $5,612.00 | 12/31/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism | No dispute reported | 06/30/2026 | 1202532606 |
| Principal investigator 1 | Genentech, Inc. | $14,793.00 | 12/19/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER PSC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211617714 |
| Principal investigator 1 | Genentech, Inc. | $456.00 | 12/19/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER PSC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211617717 |
| Principal investigator 1 | Genentech, Inc. | $1,819.00 | 12/19/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER PSC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211617728 |
| Principal investigator 1 | Eli Lilly and Company | $934.02 | 12/17/2025 | Non-covered Recipient Entity INTEND RESEARCH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187882176 |
| Principal investigator 1 | Genentech, Inc. | $832.00 | 12/11/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER PSC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211617720 |
| Principal investigator 1 | ABBVIE INC. | $18,617.20 | 12/05/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202529228 |
| Principal investigator 1 | Genentech, Inc. | $3,301.00 | 12/04/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER PSC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211617724 |
| Principal investigator 1 | Genentech, Inc. | $832.00 | 11/14/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER PSC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211617709 |
| Principal investigator 1 | ABBVIE INC. | $50,146.60 | 11/05/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202522463 |
| Principal investigator 1 | ABBVIE INC. | $38,568.60 | 10/09/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202513989 |
| Principal investigator 1 | ABBVIE INC. | $39,662.00 | 09/04/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202508988 |
| Principal investigator 1 | Eli Lilly and Company | $927.42 | 08/19/2025 | Non-covered Recipient Entity INTEND RESEARCH LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187881636 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $25.68 | 08/11/2025 | Non-covered Recipient Entity FISHER SCIENTIFIC CO LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 | No dispute reported | 06/30/2026 | 1187881176 |
| Principal investigator 1 | ABBVIE INC. | $46,361.00 | 08/06/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202502659 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $281,468.00 | 07/07/2025 | Non-covered Recipient Entity FISHER SCIENTIFIC CO LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 | No dispute reported | 06/30/2026 | 1187881530 |
| Principal investigator 1 | ABBVIE INC. | $36,470.00 | 07/03/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202496839 |
| Principal investigator 1 | ABBVIE INC. | $16,041.20 | 06/18/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202492299 |
| Principal investigator 1 | ABBVIE INC. | $67,898.60 | 06/03/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202489683 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $8,645.96 | 05/19/2025 | Non-covered Recipient Entity INTEND RESEARCH LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 | No dispute reported | 06/30/2026 | 1187882178 |
| Principal investigator 1 | ABBVIE INC. | $39,596.90 | 05/07/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202482843 |
| Principal investigator 1 | ABBVIE INC. | $8,621.20 | 04/03/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202469803 |
| Principal investigator 1 | ABBVIE INC. | $44,612.40 | 03/07/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202459418 |
| Principal investigator 1 | ABBVIE INC. | $20,833.40 | 02/06/2025 | Non-covered Recipient Entity ISIS CLINICAL RESEARCH CENTER | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202449413 |
| Principal investigator 1 | Eli Lilly and Company | $7,434.38 | 01/31/2025 | Non-covered Recipient Entity INTEND RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR | No dispute reported | 06/30/2026 | 1187881630 |
| Principal investigator 1 | Eli Lilly and Company | $1,693.61 | 01/31/2025 | Non-covered Recipient Entity INTEND RESEARCH LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187882174 |
| Principal investigator 1 | Eli Lilly and Company | $465.00 | 01/31/2025 | Non-covered Recipient Entity INTEND RESEARCH LLC | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | No dispute reported | 06/30/2026 | 1187883562 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $129,053.00 | 01/21/2025 | Non-covered Recipient Entity ATI HOLDINGS LLC DBA ATI WORKSITE SOLUTIONS | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR | No dispute reported | 06/30/2026 | 1187877119 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $250,578.00 | 01/21/2025 | Non-covered Recipient Entity FISHER SCIENTIFIC CO LLC | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | No dispute reported | 06/30/2026 | 1187882226 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $74,980.00 | 01/16/2025 | Non-covered Recipient Entity FISHER SCIENTIFIC CO LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187882228 |